Skip to main content
. 2014 Mar 26;5(9):2372–2389. doi: 10.18632/oncotarget.1706

Table 1. Clinicopathological features of 78 patients with high and low heat shock protein 90 (HSP90)-expressing mass-forming cholangiocarcinomas.

Factor HSP90 high (n = 55) HSP90 low (n = 23) P
Age (years) 58.3 ± 12.2 63.2 ± 10.9 0.086
Gender 0.713
Male 24 (43.6) 9 (39.1)
Female 31 (56.4) 14 (60.9)
Symptom 0.097
Positive 44 (80.0) 22 (95.7)
Negative 11 (20.0) 1 (4.3)
AST (IU/L) 0.564
≤ 34 29 (52.7) 10 (45.5)
> 34 26 (47.3) 12 (54.5)
ALT (U/L) 0.357
≤ 36 27 (52.9) 13 (65.0)
> 36 24 (47.1) 7 (35.0)
ALP (U/L) 0.491
≤ 94 15 (28.3) 8 (36.4)
> 94 38 (71.7) 14 (63.6)
Bilirubin (total) (mg/dL) 0.934
≤ 1.3 45 (81.8) 19 (82.6)
> 1.3 10 (18.2) 4 (17.4)
Albumin (g/dL) 0.226
≤ 3.5 13 (26.5) 9 (40.9)
> 3.5 36 (73.5) 13 (59.1)
Serum CEA (ng/mL) 0.984
≤ 5 17 (44.7) 8 (44.4)
> 5 21 (55.3) 10 (55.6)
Size (cm) 0.843
≤ 5 23 (43.4) 9 (40.9)
> 5 30 (56.6) 13 (59.1)
Lymph node 0.076
Negative 38 (69.1) 11 (47.8)
Positive 17 (30.9) 12 (52.2)
Differentiated 0.131
Well 1 (1.8) 1 (4.3)
Moderate 29 (52.7) 12 (52.2)
Poorly 25 (45.5) 8 (34.8)
Other 0 2 (8.7)
Post-op chemotherapy 0.254
No 21 (38.2) 12 (52.2)
Yes 34 (61.8) 11 (47.8)
Post-op radiotherapy 0.266
No 46 (83.6) 22 (95.7)
Yes 9 (16.4) 1 (4.3)